Restricted accessResearch articleFirst published online 2017-10
Rethinking Cancer Treatment from Maximum Tolerated Dose to Immune Therapies or Low-Dose Chemotherapy Treatments: A Clinical Conversation with Mark Rosenberg,MD,and Robert Rountree,MD
GatenbyRA, SilvaAS, GilliesRJ, FriedenBR. Adaptive therapy. Cancer Res, 2009; 69:4894–4903.
2.
LorenteD, MateoJ, de BonoJS. Molecular characterization and clinical utility of circulating tumor cells in the treatment of prostate cancer. Am Soc Clin Oncol Educ Book, 2014; e197–203.
3.
KulasingheA, PerryC, JovanovicL, et al.Circulating tumour cells in metastatic head and neck cancers. Int J Cancer, 2015; 136:2515–2523.
4.
LvQ, GongL, ZhangT, et al.Prognostic value of circulating tumor cells in metastatic breast cancer: A systemic review and meta-analysis. Clin Transl Oncol, 2016; 18:322–330.
5.
FioriME, VillanovaL, De MariaR. Cancer stem cells: At the forefront of personalized medicine and immunotherapy. Curr Opin Pharmacol, 2017; 35:1–11.
6.
Rodríguez-UbrevaJ, Garcia-GomezA, BallestarE. Epigenetic mechanisms of myeloid differentiation in the tumor microenvironment. Curr Opin Pharmacol, 2017; 35:20–29.
7.
AlfaroukKO. Tumor metabolism, cancer cell transporters, and microenvironmental resistance. J Enzyme Inhib Med Chem, 2016; 31:859–866.
8.
JustusCR, SanderlinEJ, YangLV. Molecular connections between cancer cell metabolism and the tumor microenvironment. Int J Mol Sci, 2015; 16:11055–11086.
9.
ZhangX, de MilitoA, OlofssonMH, et al.Targeting mitochondrial function to treat quiescent tumor cells in solid tumors. Int J Mol Sci, 2015; 16:27313–27326.
10.
WinterSF, LoebelF, DietrichJ. Role of ketogenic metabolic therapy in malignant glioma: A systematic review. Crit Rev Oncol Hematol, 2017; 112:41–58.
11.
AngelesTS, HudkinsRL. Recent advances in targeting the fatty acid biosynthetic pathway using fatty acid synthase inhibitors. Expert Opin Drug Discov, 2016; 11:1187–1199.
12.
GrassoC, JansenG, GiovannettiE. Drug resistance in pancreatic cancer: Impact of altered energy metabolism. Crit Rev Oncol Hematol, 2017; 114:139–152.
13.
OhGS, KimHJ, ShenA, et al.New therapeutic concept of NAD redox balance for cisplatin nephrotoxicity. Biomed Res Int, 2016; 2016:404839–0.
14.
RussoGL, TedescoI, SpagnuoloC, RussoM. Antioxidant polyphenols in cancer treatment: Friend, foe or foil?. Semin Cancer Biol, 2017May13. DOI: 10.1016/j.semcancer.2017.05.005 [Epub ahead of print].
15.
BrandhorstS, LongoVD. Fasting and caloric restriction in cancer prevention and treatment. Recent Results Cancer Res, 2016; 207:241–266.
16.
HuF, XuY, LiuF. Hypothalamic roles of mTOR complex I: integration of nutrient and hormone signals to regulate energy homeostasis. Am J Physiol Endocrinol Metab, 2016; 310:E994–E1002.
17.
HirschHA, IliopoulosD, TsichlisPN, StruhlK. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res, 2009; 69:7507–7511.
TolaneyS, SavulskyC, AktanG, et al.Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer. Presented at 2016 San Antonio Breast Cancer Symposium, December6–10, 2016, San Antonio, TX. Abstract P5-15-02.
